---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-085658"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:18:33.360011+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics gets Nasdaq extension to Feb 2026 for bid price compliance; transfers to Capital Market

## Summary
- Received 180-day extension until Feb 23, 2026 to meet $1.00 minimum bid price rule after Aug 26 initial deadline.
- Nasdaq approved transfer from Global Select to Capital Market effective Aug 27, 2025; stock continues under IPSC.
- Company will consider a reverse stock split to cure the bid price deficiency.
- No assurance of regaining compliance; delisting remains possible if price fails to close at $1.00 for 10 consecutive days.

## SEC filing metadata
- accession: 0001104659-25-085658
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465925085658/0001104659-25-085658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465925085658/tm2524509d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-085658
- JSON: https://secwatch.observer/filing/0001104659-25-085658.json
- Plain text: https://secwatch.observer/filing/0001104659-25-085658.txt

## Key facts
- Listing & Compliance Notices
  Century Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: August 27, 2025, Nasdaq notified the Company that it had granted the Company an additional 180 calendar day period, or until February 23, 2026 (the “ Extended Compliance Date ”), to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on, among other things, (1) the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and (2) the Company’s written notice of its intention to cure the deficiency by effecting a reverse sto
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465925085658/0001104659-25-085658-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.